Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The lawsuit, filed by The Rosen Law Firm, alleges that ADMA Biologics misled the market during the specified period. According to the complaint, the company failed to disclose an undisclosed related party transaction and allegedly utilized channel stuffing to artificially inflate revenue figures. The plaintiffs contend that these actions left the company without adequate internal controls, resulting in materially false statements regarding its business operations.

Investors who purchased shares during this window may be eligible for compensation under a contingency fee arrangement, meaning no out-of-pocket costs are required to participate. While the lawsuit has been filed, no class has yet been certified. Shareholders retain the option to hire their own counsel, remain an absent class member, or move to act as a lead representative to direct the litigation. Interested parties should contact Phillip Kim at The Rosen Law Firm before the August 10 cutoff to formalize their involvement.